Evidence-based articles on weight loss, GLP-1 medications, nutrition, and metabolic health. Written and reviewed by board-certified physicians.
A comprehensive guide to the triple-agonist mechanism behind retatrutide (GLP-3), including clinical trial data showing 30%+ body weight reduction, pharmacokinetics, and how it compares to semaglutide and tirzepatide.
A patient presents with a BMI of 38, newly diagnosed hypertension, and no personal or family history of medullary thyroid carcinoma. The clinical question — tirzepatide or semaglutide — previously…
The Patient Who Stopped Too Soon A 47-year-old woman, 214 lbs at peak, had worked down to 171 lbs over 14 months on semaglutide 2.4 mg weekly. She felt great. Her physician agreed she could take a…
When Weight Loss Becomes a Sleep Apnea Treatment Picture a 54-year-old patient — moderately obese, CPAP-dependent for six years, compliance at maybe 60% on a good month. He shows up to a weight…
A Problem That Weight Loss Alone Wasn't Solving Picture a 54-year-old male patient — 118 kg, BMI 38, moderate-to-severe obstructive sleep apnea confirmed by polysomnography. He's been on CPAP for…
The Problem Nobody Talks About When Patients Start GLP-1 Therapy A 52-year-old male patient starts semaglutide at 0.25 mg/week. By week 12, he's down 18 pounds — but he's also reporting a nagging…
The Shortage Is Over — But the Access Problem Isn't In February 2025, the FDA officially removed semaglutide from its drug shortage database. On paper, that sounds like a win. In practice…
The Problem Nobody Warned Their Patients About A 54-year-old woman comes back for her 12-week semaglutide check-in. She's down 22 pounds. Her physician is thrilled. But when you pull up her DEXA…
Why the Retatrutide Phase 3 Readout Is the Most-Watched Trial in Metabolic Medicine Right Now Imagine running a weight management clinic. Your best patients on semaglutide 2.4 mg hit a wall at…
Two Drugs, One Question: Which Actually Moves the Needle? A patient walks into a weight management clinic having already tried liraglutide (Victoza/Saxenda) for 52 weeks. They lost 6% of their body…
Tirzepatide reset the weight-loss benchmark in 2022. Three years later the comparative-effectiveness data has caught up, and the answer to "is tirzepatide better than semaglutide for obesity?" is…
Tirzepatide reset the weight-loss benchmark in 2022. Three years later the comparative-effectiveness data has caught up, and the answer to "is tirzepatide better than semaglutide for obesity?" is…
Reconstitution diluent selection is one of the more consequential — and most under-documented — decisions in peptide research. The two diluents in widest use, bacteriostatic water for injection…
Semaglutide vs tirzepatide vs retatrutide: a data-driven comparison of efficacy, side effects, cost, and clinical trial results to help you choose the right medication.
Everything you need to know about GLP-1 side effects: what to expect, how to manage nausea and GI symptoms, when to contact your physician, and long-term safety data.
Clinical evidence, mechanism of action, and treatment protocols for GLP-1 and GLP-3 weight loss therapies. Sourced from peer-reviewed trials and medical literature.
An introduction to the GLP3 Weight Loss platform: how our telehealth programs work, what makes us different, and what to expect from your first consultation.
A practical, evidence-based guide to GLP-1 weight loss therapy. Covers eligibility, medication options, expected results, and how to get started with treatment.
Understand how GLP3 Weight Loss is different from other telehealth weight loss providers. Our approach, our physicians, and our commitment to evidence-based care.